Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain
Mucosal monoclonal CD3 antibody (CD3 mAb) protects NOD mice from diabetes. Oral administration of CD3 mAb decreases diabetogenicity of effector T cells. Oral CD3 mAb increases the number and function of regulatory T cells.